论文部分内容阅读
目的:观察研究舒筋活络丸联合苏肽生治疗小儿痉挛型脑瘫的临床疗效。方法:选取我科室2013年1月至2014年1月收治疗的确诊为小儿痉挛型脑瘫的患者共60例,按随机数字表法分为观察组和对照组各30例,对照组给予苏肽生治疗,观察组在予苏肽生治疗基础上给予舒筋活络丸治疗,记录治疗前各组患儿相关指标,且随访并记录治疗10个疗程后两组患儿血清IL-4、IFN-γ及TNF-α值变化情况和一年半后韦氏儿童智力量表评分、粗大功能评定量表评分、日常生活能力评定指数、发育商评分和痉挛程度,将两组患儿情况进行治疗前后和组间对比分析。结果:观察组患者治疗后韦氏儿童智力量表评分、粗大功能评定量表评分、日常生活能力评定指数值分别为(65.2±6.4、64.8±7.3、63.3±5.9)分,均明显优于对照组(55.5±5.1、46.9±7.0、54.3±5.2)分。观察组患者治疗后发育商评分为66.39±6.02分,明显优于对照组56.36±5.21分。观察组治疗后痉挛程度分值为2.73±0.27分,明显优于对照组3.60±0.30分。4观察组治疗后血清IL-4、IFN-γ及TNF-α值分别为(15.48±1.37、20.82±3.17、13.54±1.86)ng/L,均明显优于对照组(21.64±2.65、31.82±3.64、24.95±2.33)ng/L。5观察组治疗后CT检测结果异常率为33.33%,低于对照组60.00%,且差异有显著性(p<0.05)。结论:舒筋活络丸联合苏肽生治疗小儿痉挛型脑瘫的临床治疗效果确切。
Objective: To observe the clinical efficacy of Shujin Huoluo pills combined with Su peptide in children with spastic cerebral palsy. Methods: A total of 60 patients diagnosed as pediatric spastic cerebral palsy admitted to our department from January 2013 to January 2014 were randomly divided into observation group (30 cases) and control group (30 cases), and control group The patients in observation group were treated with Shujinhuoluo pills on the basis of pretreatment with Supeptide, and the indexes of children in each group were recorded before and after treatment. After 10 courses of treatment, the levels of IL-4 and IFN- γ and TNF-α values and the scores of Wechsler Children’s Intelligence Scale, Gross Function Scale, Daily Life Capability Index, Developmental Scale and Spasticity in the first year and a half after the treatment, before and after treatment And comparative analysis between groups. Results: After treatment, the scores of Wechsler Intelligence Scale, Gross Function Rating Scale and Daily Life Ability Evaluation Index in the observation group were (65.2 ± 6.4,64.8 ± 7.3,63.3 ± 5.9) points, which were significantly better than those in the control Group (55.5 ± 5.1, 46.9 ± 7.0, 54.3 ± 5.2) points. After treatment, the score of the developers in the observation group was 66.39 ± 6.02, which was significantly better than that of the control group (56.36 ± 5.21). Observation group after treatment spasticity score was 2.73 ± 0.27 points, significantly better than the control group 3.60 ± 0.30 points. The levels of IL-4, IFN-γ and TNF-α in the observation group were (15.48 ± 1.37, 20.82 ± 3.17 and 13.54 ± 1.86) ng / L, which were significantly better than those in the control group (21.64 ± 2.65 and 31.82 ± 3.64, 24.95 ± 2.33) ng / L. 5 The observation group after treatment CT abnormality rate was 33.33%, lower than the control group 60.00%, and the difference was significant (p <0.05). Conclusion: Shujinhuoluo pills combined with Su peptide in children with spastic cerebral palsy clinical treatment effect is exact.